Ogata, Hiroaki http://orcid.org/0000-0002-0046-5575
Fukagawa, Masafumi
Hirakata, Hideki
Kagimura, Tatsuo
Akizawa, Tadao
,
Funding for this research was provided by:
Bayer Yakuhin Ltd. Bayer Yakuhin Ltd
Article History
Received: 27 May 2022
Accepted: 23 August 2022
First Online: 5 September 2022
Declarations
:
: Dr Ogata reported receiving lecture fees from Bayer Yakuhin, Kyowa Kirin, Torii Pharmaceutical, Otsuka, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharm, Daiichi Sankyo, Kowa, Ono Pharmaceutical; grants from Torii Pharmaceutical and Ono Pharmaceutical; and consulting fees from YL Biologics. Dr Fukagawa reported receiving personal fees from Bayer Yakuhin and grants from Kyowa Kirin. Dr Hirakata reported receiving personal fees from Kyowa-Kirin, Chugai Pharma, Torii, Japan Tobacco, and Ono Yakuhin. Dr Kagimura reported receiving grants from Bayer Yakuhin. Dr Akizawa reported receiving consulting and lecture fees from Bayer Yakuhin, Astellas, Kyowa Kirin, Kissei Pharmaceutical, Ono Pharmaceutical, Fuso Pharmaceutical Industry, Torii Pharmaceutical; consulting fees from GlaxoSmithKline, JT Pharmaceutical, Nipro Corporation, Otsuka, and Sanwa Chemical; and lecture fees from Chugai Pharmaceutical. No other disclosures were reported.
: The trial protocol of the LANDMARK study was previously published and was approved by the Institutional Review Board. All patients enrolled in this LANDMARK-SS study provided written informed consent.